Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2008 Jan 17;31(1):30–34. doi: 10.1002/clc.20175

Factors Associated with Non‐adherence to Therapy with Warfarin in a Population of Chronic Heart Failure Patients

Salpy V Pamboukian 1,✉, Imran Nisar 2, Sheetal Patel 2, Liping Gu 2, Mary McLeod 2, Maria Rosa Costanzo 3, Alain Heroux 4
PMCID: PMC6653211  PMID: 18203116

Abstract

Background

Adherence to heart failure therapy is important in reducing morbidity and mortality over the course of the disease process. The aim of this study was to examine factors associated with non‐adherence to warfarin in chronic heart failure patients.

Methods

Eighty patients receiving warfarin therapy in 2002 were included. Adherence was defined as maintenance of international normalized ratio (INR) between 2 and 3.5 and keeping scheduled appointments for INR checks at least 75% of the time. Clinical variables examined included age, gender, race, insurance, left ventricular ejection fraction (LVEF), etiology, New York heart association (NYHA) class, comorbidities, smoking, and alcohol use.

Results

Of 80 patients studied, 59 were male with mean age ( ± standard deviation) 52 ± 13 years, 24 had ischemic etiology with mean LVEF of 24% ± 9%. Non‐adherence was associated with tobacco use, odds ratio of 6.5 (p <0.01). Ischemic etiology was associated with adherence, odds ratio of 4.5 (p <0.01). Non‐adherent patients were more likely to be insured with Medicare/Medicaid (p = 0.04) and have better NYHA class (p = 0.04). Adherence positively correlated with older age and lower LVEF, and negatively correlated with number of hospitalizations (p<0.01 for all). In a multiple regression model, patients with improvement in LVEF had decreased adherence over the year (p<0.01).

Conclusions

The profile of heart failure patients who demonstrated non‐adherence to warfarin therapy included younger age, nonischemic etiology, better NYHA class, smoking, insurance with Medicare/Medicaid and improved LVEF over the study. Measures targeting these patients may result in improved adherence to other pharmacologic treatments of heart failure. Copyright © 2008 Wiley Periodicals, Inc.

Keywords: heart failure, cardiac transplantation, cardiomyopathy, myocarditis

Full Text

The Full Text of this article is available as a PDF (235.1 KB).

References

  • 1.National Center for Health Statistics. Deaths: Final Data for 2000. Nat Vital Stat Rep 2002; 50: 1–120. [PubMed] [Google Scholar]
  • 2.American Heart Association. Heart Disease and Stroke Statistics–2003 Update. Dallas, TX: American Heart Association, 2002. [Google Scholar]
  • 3. Haynes RB: Introduction In Compliance in Health Care (Eds. Haynes RB, Taylor DW, Sackett KL.), pp 1–7. Baltimore: The Johns Hopkins University Press, 1979. [Google Scholar]
  • 4. Claxton AJ, Cramer J, Pierce C: A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296–1310. [DOI] [PubMed] [Google Scholar]
  • 5. Bohachick P, Burke LE, Sereika S, Murali S, Dunbar‐Jacob J: Adherence to angiotensin‐converting enzyme inhibitor therapy for heart failure. Prog Cardiovasc Nurs 2002; 17: 160–166. [DOI] [PubMed] [Google Scholar]
  • 6. Ghali JK, Kadakis S, Cooper R, Ferlinz J: Precipitating factors leading to decompensation of heart failure. Arch Intern Med 1988; 148: 2013–2016. [PubMed] [Google Scholar]
  • 7. Chui MA, Deer M, Bennett SJ, Tu W, Oury S, et al.: Association between adherence to diuretic therapy and health care utilization in patients with heart failure. Pharmacotherapy 2003; 23: 326–332. [DOI] [PubMed] [Google Scholar]
  • 8. Hope CJ, Wu J, Tu W, Young J, Murray MD: Association of medication adherence, knowledge, and skills with emergency department visits by adults 50 years or older with congestive heart failure. Am J Health Syst Pharm 2004; 61: 2043–2049. [DOI] [PubMed] [Google Scholar]
  • 9. N Engl J Med Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. 1991; 325: 293–302. [DOI] [PubMed] [Google Scholar]
  • 10. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, et al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1196; 334: 1349–1355. [DOI] [PubMed] [Google Scholar]
  • 11. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, et al.: The effect of spironolactone on morbidity and mortality in patients with sever heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709–717. [DOI] [PubMed] [Google Scholar]
  • 12. Balkrishnan R: Predictors of medication adherence in the elderly. Clin Ther 1998; 20: 764–771. [DOI] [PubMed] [Google Scholar]
  • 13. Lee JK, Grace KA, Taylor AJ: Effect of a pharmacy care program on medication adherence and persistence, blood pressure and low density lipoprotein concentration. JAMA 2006; 296: 2563–2571. [DOI] [PubMed] [Google Scholar]
  • 14. Rasmussen JN, Chong A, Alter DA: Relationship between adherence to evidence‐based pharmacotherapy and long term mortality after acute myocardial infarction. JAMA 2007; 297: 177–186. [DOI] [PubMed] [Google Scholar]
  • 15. Osterberg L, Blaschke T: Adherence to medication. N Engl J Med 2005; 353: 487–497. [DOI] [PubMed] [Google Scholar]
  • 16. Waterman AD, Milligan PE, Bayer L, Banet GA, Gatchel SK, et al.: Effect of warfarin non‐adherence on control of the International Normalized Ratio. Am J Health Syst Pharm 2004; 61: 1258–1264. [DOI] [PubMed] [Google Scholar]
  • 17. Arnsten JH, Gelfand JM, Singer DE: Determinants of compliance with anticoagulation: a case control study. Am J Med 1997; 103: 11–17. [DOI] [PubMed] [Google Scholar]
  • 18. Evangelista LS, Doering LV, Dracup K, Westlake C, Hamilton M, et al.: Compliance behaviors of elderly patients with advanced heart failure. J Cardiovasc Nurs 2003; 18: 197–206. [DOI] [PubMed] [Google Scholar]
  • 19. Roe CM, Motheral BR, Teitelbaum F, Rich MW: Compliance with and dosing of angiotensin‐converting enzyme inhibitors before and after hospitalization. Am J Health Syst Pharm 2000; 57: 139–145. [DOI] [PubMed] [Google Scholar]
  • 20. Ammassari A, Trotta MP, Murri R, Castelli F, Narciso P, et al.: Correlates and predictors of adherence to highly active antiretroviral therapy: overview of the published literature. J Acquir Immune Defic Syndr 2002; 31: S123–S127. [DOI] [PubMed] [Google Scholar]
  • 21. Monane M, Bohn RL, Gurwitz JH: Compliance with antihypertensive therapy among elderly Medicaid enrollees: the roles of age, gender and race. Am J Public Health 1996; 86: 1805–1808. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Sharkness CM, Snow DA: The patient's view of hypertension and compliance. Am J Prev Med 1992; 8: 141–146. [PubMed] [Google Scholar]
  • 23. Miller NH, Hill M, Kottke T, Ockene IS: The multilevel compliance challenge: recommendations for a call to action. A statement for healthcare professionals. Circulation 1997; 95: 1085–1090. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES